Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe plus high-intensity statin versus high-intensity statin alone in acute coronary syndrome
IRCT20250528065945N1Phase 2Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ezetimibe, rosuvastatin and atorvastatin in acute coronary syndrome (ACS) and coronary arteriosclerosis (4 arms), sponsored by Shahrekord University of Medical Sciences. Primary endpoints: Lipid profile, High-sensitivity C-reactive protein and 1 more. Started Oct 2025; status: completed.
02
Drugs
ezetimiberosuvastatinatorvastatin
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20250528065945N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250528065945N1.